๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› NSCLC
Clinical trial register · China

NSCLC Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 18 Beijing 15 Changsha 10 Hangzhou 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital5 Shanghai Chest Hospital4 Fudan University3 Allist Pharmaceuticals, Inc.3 Sichuan University3
Site location
Shanghai18 Guangzhou18 Beijing15 Changsha10 Hangzhou8
All 39 locations
Target enrolment
to

NSCLC trials in China

83 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
NCT07697586NSCLC
DrugsSKB118·Sacituzumab tirumotecan
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
206
Jilin City, Shanghai
2026-08-07
Not yet open
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
NCT07358689NSCLC
DrugsDiphenhydramine·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2026-06-30
Not yet open
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
NCT07692048NSCLC
DrugSYS6010
Sichuan University
Phase 1
21
Chengdu
2026-06-30
Recruiting
Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
NCT07612722NSCLC
Wen-zhao ZHONG
Not applicable
585
Guangzhou
2026-05-18
Not yet open
Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC
NCT07643350NSCLC
DrugEtoposide
The Third Xiangya Hospital of Central South University
Phase 2
152
Changsha
2026-05-15
Not yet open
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
NCT07413952NSCLC
DrugLimertinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
45
Guangzhou
2026-04-01
Recruiting
SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study
NCT07670013NSCLC
DrugSacituzumab tirumotecan
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
43
Hangzhou
2026-04-01
Not yet open
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
NCT07379398NSCLC
DrugsLparomlimab and Tuvonralimab·SBRT
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-04-01
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
NCT07274813Advanced/Metastatic Solid Tumors, NSCLC
Shanghai Henlius Biotech
Phase EARLY_PHASE1
254
Shanghai, Xi'an
2025-12-29
Not yet open
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
NCT07286942NSCLC, NSCLC (Non-small Cell Lung Cancer)
DrugIparomlimab and Tuvonralimab
Jiangsu Cancer Institute & Hospital
Phase 2
24
Nanjing
2025-12-18
Recruiting
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
NCT07169552NSCLC
DrugHC010
HC Biopharma Inc.
Phase 2
50
Shanghai
2025-12-09
Recruiting
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer๏ผˆNSCLC๏ผ‰
NCT07388771NSCLC, Neoadjuvant Therapy
Qian Chu
Observational
500
Wuhan, Hangzhou
2025-12-01
Recruiting
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
NCT07330037NSCLC
DrugTislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
41
Tianjin
2025-12-01
Recruiting
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
NCT07793500NSCLC, Advanced Solid Tumor
DrugYSCH-01
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
36
Beijing
2025-11-27
Recruiting
A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer
NCT07647094NSCLC
People's Hospital of Quzhou
Phase EARLY_PHASE1
112
Quzhou
2025-11-01
Recruiting
RGL-270 + ICI in Advanced NSCLC
NCT07652125NSCLC
Guangdong Association of Clinical Trials
Not applicable
40
Guangzhou
2025-10-25
Not yet open
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604NSCLC, Neoadjuvant Therapy
DrugVebreltinib Enteric
Fudan University
Phase 2
30
Shanghai
2025-09-30
Not yet open
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
NCT07198321Cancer, PDAC, CRC (Colorectal Cancer), NSCLC
DrugGFH276
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
450
Guangzhou
2025-09-22
Not yet open
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
NCT07179445NSCLC
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2025-09-20
Recruiting
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
NCT07082179NSCLC
DrugsCisplatin/carboplatin·Iparomlimab and Tuvonralimab
Jiangsu Cancer Institute & Hospital
Phase 2
33
Nanjing
2025-09-04
Recruiting
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT07181499NSCLC, Adjuvant Drug Therapy, EGFR
DrugsBefotertinib·Pemetrexed·Carboplatin
Betta Pharmaceuticals Co., Ltd.
Phase 2
28
Guangzhou, Zhuhai
2025-09
Recruiting
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
NCT07138755NSCLC, Sintilimab, Adaptive Radiotherapy
The Third Xiangya Hospital of Central South University
Phase 2
35
Changsha, Hengyang, Jishou
2025-08-29
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
DrugsPenpulimab·Bevacizumab
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
NCT07089199NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
Qilu Hospital of Shandong University
Phase 2
34
Jinan
2025-07-25
Recruiting
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy๏ผˆFIRMOST๏ผ‰
NCT07010419NSCLC, Adjuvant Treatment
DrugFirmonertinib
Allist Pharmaceuticals, Inc.
Phase 3
338
Beijing, Guangdong
2025-05-28
Active, closed
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
NCT06944470NSCLC
DrugsJS207·Paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
78
Guangzhou
2025-05-20
Recruiting
PET/CT for Trop2 ADC Response Evaluation NSCLC
NCT07151898NSCLC, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2025-05-01
Active, closed
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
NCT06940401NSCLC
DrugJS111
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2
44
Shanghai
2025-04-30
Recruiting
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
NCT07092202Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor
DrugsFirmonertinib·Pemetrexed
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4
40
Wuhan
2025-04-15
Recruiting
Adaptive Therapy for Resected Stage โ… A2-โ…ก NSCLC Patients With Undetectable MRD
NCT06924710NSCLC
Peking University Cancer Hospital & Institute
Not applicable
286
Beijing
2025-04-06
Recruiting
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
NCT06945705NSCLC
DrugsFurmonertinib·Anlotinib
Henan Cancer Hospital
Phase 2
146
Zhengzhou
2025-04-02
Recruiting
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
NCT06844474NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
300
Beijing
2025-03-07
Recruiting
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
NCT05798845NSCLC
DrugTislelizumab
Shanghai Chest Hospital
Phase 2
124
Shanghai
2025-02-20
Recruiting
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
NCT06864624NSCLC
DrugSunvozertinib
Tang-Du Hospital
Phase 2
27
Changsha, Yinchuan, Xi'an
2025-02-18
Recruiting
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
NCT06738160NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy
Fudan University
Phase 2
27
Shanghai
2025-02-15
Recruiting
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
NCT06754644NSCLC
DrugsQL2107·Pemetrexed·Carboplatin·Pembrolizumab
Qilu Pharmaceutical Co., Ltd.
Phase 3
808
Jinan
2025-01-15
Not yet open
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
NCT06735508NSCLC
Guangdong Provincial People's Hospital
Phase EARLY_PHASE1
40
Guangzhou
2025-01
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
NCT06739031NSCLC
Energenx Medical LTD.
Not applicable
126
Shanghai
2024-12-25
Recruiting
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
NCT06714708NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy, Sintilimab
Anhui Provincial Cancer Hospital
Phase 2
86
Hefei
2024-11-20
Not yet open
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
NCT06684873NSCLC, Brain Metastasases
DrugBevacizumab
Sun Yat-sen University
Phase 2
55
Guangzhou
2024-11-02
By invitation
Perioperative Treatment Outcomes of Early NSCLC
NCT06610240NSCLC
Shanghai Chest Hospital
Observational
500
Shanghai
2024-11-01
Active, closed
A Prospective Observational Study of Changes in Cortisol Levels After Neoadjuvant Immunotherapy and Their Prognostic Value in Patients With NSCLC
NCT07530276NSCLC
Guangdong Provincial People's Hospital
Observational
330
Guangzhou
2024-08-30
Recruiting
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
NCT06532591NSCLC
DrugsCadonilimab·Carboplatin
Sichuan Cancer Hospital and Research Institute
Phase 2
20
Chengdu
2024-08-01
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
NCT06534762NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
DrugMirabegron
Zhejiang Provincial People's Hospital
Phase 2
260
Hangzhou
2024-07-15
Active, closed
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
NCT06448910NSCLC, Locally Advanced Lung Carcinoma
Fudan University
Phase 2
41
Shanghai
2024-07-01
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSac-TMT·Nab-paclitaxel·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Not yet open
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
NCT06465238NSCLC
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2024-06
Recruiting
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
NCT06431685NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
DrugsPemetrexed·Tislelizumab
Sichuan University
Phase 1
10
Chengdu
2024-04-25
Recruiting
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
NCT06221670NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
51
Tianjin
2024-03-20
Recruiting
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
NCT06317558NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2024-03-01
Not yet open
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
NCT06054191NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
DrugsCapmatinib·Dabrafenib·Trametinib
Sun Yat-sen University
Phase 2
40
Guangzhou
2024-02-01
Recruiting
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer๏ผšA Prospective, Single-Arm, Phase II Study
NCT07085182NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
DrugsTislelizumab followed by Tislelizumab·SBRT
Zibo Municipal Hospital
Phase 2
20
Zibo
2024-01-13
Recruiting
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
NCT05991193NSCLC
Hunan Province Tumor Hospital
Observational
100
Changsha
2023-12-29
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
NCT06142058Evaluation, NSCLC, Targeted Therapy
Xueqin Yang
Observational
44
Chongqing
2023-11-13
Recruiting
Study on c-Met Targeted PET/CT Imaging in NSCLC
NCT06911697PET/CT Imaging, NSCLC
Xilin Sun
Not applicable
88
Harbin
2023-10-26
Recruiting
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
NCT07247227NSCLC
Peking Union Medical College
Not applicable
150
Beijing
2023-10-10
Recruiting
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05948813NSCLC, EGFR Activating Mutation, Brain Metastases
DrugOsimertinib
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Recruiting
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
NCT05994131NSCLC
DrugsIN10018·Furmonertinib
InxMed (Shanghai) Co., Ltd.
Phase 1/2
110
Shanghai
2023-07-13
Recruiting
Safety and Efficacy of NK510 to Treat NSCLC
NCT06097962NSCLC
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
12
Nanjing
2023-07-01
Active, closed
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
NCT05756972NSCLC
DrugsPumitamig·Pemetrexed·Carboplatin
Biotheus Inc.
Phase 2
64
Guangzhou
2023-06-26
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
NCT05882513NSCLC, Neoadjuvant Therapy
DrugSerplulimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Recruiting
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980NSCLC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab deruxtecan·Dato-DXd·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Active, closed
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
NCT05466149NSCLC
DrugFurmonertinib
Allist Pharmaceuticals, Inc.
Phase 2
100
Changchun
2022-09-27
Recruiting
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Recruiting
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321Advanced Solid Tumor, NSCLC
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Jinan
2022-08-25
Recruiting
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
NCT05286957NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 2
60
Zhengzhou
2022-06-20
Recruiting
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NCT05382728NSCLC, EGFR Activating Mutation
TYK Medicines, Inc
Phase 3
680
Changsha, Shanghai
2022-06-08
Not yet open
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
NCT05132985NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Liaoning Cancer Hospital & Institute
Phase 2
45
Shenyang
2022-01-01
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
NCT05615142NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy, PD-1 Inhibitor
Sichuan University
Phase 1
9
Chengdu
2021-12-15
Active, closed
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
NCT05078931NSCLC
DrugsLenvatinib·Pembrolizumab
Shanghai Chest Hospital
Phase 2
35
Shanghai
2021-10-27
Active, closed
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
NCT05009329NSCLC, Solid Tumor
Allist Pharmaceuticals, Inc.
Phase 1/2
315
Beijing
2021-07-26
Recruiting
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
NCT07198217NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
DrugsTislelizumab followed by Tislelizumab·SBRT
Zibo Municipal Hospital
Phase 2
20
Zibo
2021-05-25
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
DrugAlectinib
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Recruiting
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
NCT04686682NSCLC, SCLC, CRPC, ESCC
DrugJAB-8263
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
152
Tianjin
2021-05-07
Active, closed
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
NCT04736823NSCLC
DrugsPemetrexed·Carboplatin·Bevacizumab·Paclitaxel
Akeso
Phase 2
265
Guanzhou
2021-02-01
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512Lung, Lung Cancer, Cancer, NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2019-06-01
Recruiting
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
NCT05701787NSCLC, NSCLC Stage IV, NSCLC, Recurrent
Shanghai Chest Hospital
Observational
500
Shanghai
2019-01-01
Recruiting
Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
NCT04522687NSCLC, Esophageal Squamous Cell Carcinoma, Thymic Epithelial Tumor
Shanghai Cancer Hospital, China
Observational
500
Shanghai
2012-01-01
Rows per page Showing 1–83 of 83
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/nsclc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 83 of those studies listing the condition NSCLC.

How many NSCLC trials are recruiting in China?

52 of the 83 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 15 have not yet opened recruitment, 15 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (NSCLC), 83 studies
PhaseStudiesRecruitingShare
Phase 2402248.2%
Observational12814.5%
Not applicable667.2%
Phase 1647.2%
Phase 1/2637.2%
Phase 3546%
Phase EARLY_PHASE1546%
Phase 4313.6%

Most active sponsors

Lead sponsors with the most studies (NSCLC)
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital52
Shanghai Chest Hospital42
Allist Pharmaceuticals, Inc.31
Fudan University31
Sichuan University31
Betta Pharmaceuticals Co., Ltd.22
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Guangdong Provincial People's Hospital20
Henan Cancer Hospital21
Jiangsu Cancer Institute & Hospital21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.